Treatment for Hormone Sensitive Prostate Cancer

CME Available: https://auau.auanet.org/node/38703

Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion.

At the conclusion of this activity, participants will be able to:

1. Apply the AUA Clinical Guidelines for Advanced Prostate Cancer for the treatment of HSPC.

2. Summarize the current utilization of treatment intensification in HSCP and apply appropriate treatment intensification in men with HSPC.

3. Describe the current indications, potential benefits and adverse events that may occur with use of doublet and triplet regimens as compared to SOC in HSPC.

4. Identify opportunities for shared care and team-based approaches to offer state-of-the-art evidenced care for HSPC.

5. Facilitate discussions with patients and caregivers to engage them in the HSPC treatment plan.

ACKNOWLEDGEMENT

This educational activity is supported by an independent educational grant from:

Astellas

Pfizer, Inc.